Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Nomic Omni 1000 immunoassay platform into BCL’s omics offerings. The collaboration is intended to combine broad protein immunoassay coverage with BCL’s genomic disease-risk models and precision oncology workflows, including use in clinical trials and multiomic studies. Nomic said its Omni 1000 uses nELISA technology to multiplex hundreds to thousands of immunoassays quickly without antibody cross-reactivity, and supports absolute quantification for more than 1,050 proteins. Initial development work is underway, with joint applications planned to be offered in early 2027. The deal reflects continued investment in scalable proteomics infrastructure aimed at making protein biomarkers more comparable to other modalities in translational research.